GERMAN EARLY BENEFIT ASSESSMENTS OF ORPHAN DRUGS UNDER FULL DOSSIER CONDITIONS

Author(s)

Kirchmann T1, Schönermark M1, Ewald A2
1SKC Beratungsgesellschaft mbH, Hannover, Germany, 2Medizinische Hochschule Hannover, Hannover, Germany

OBJECTIVES: Market access in Germany provides several advantages for orphan drugs in the course of the early benefit assessment, since the additional benefit is already granted by law on the basis of the marketing authorization and its substantiating studies. However, this no longer applies if the drug’s turnovers exceed 50 million euro over the past 12 months leading to additional requirements along the benefit assessment, including the comparison against an appropriate comparative therapy.

METHODS: All published documents of the early benefit assessments of those orphan drugs whose turnovers exceeded the 50-million-euro threshold over the past 12 months until June 2018 were analyzed in terms of the available evidence, appropriate comparative therapy, G-BA’s methodology and negotiated prices.

RESULTS: In total, 6 orphan drugs have exceeded the 50-million-euro turnover threshold so far. Five of them were oncologics, one a cardiological drug. While all but one oncology drugs were able to confirm the previously granted additional benefit, the cardiological one failed to prove benefitial compared to a patient-individually optimized drug therapy acc. to the physician's requirements. To date, price negotiations for 4 of the 6 re-assessments are completed. Negotiated rebates of oncological drugs show no outliers and confirm the value of the re-assessment, but rebate of macitentan demonstrates the major challenge of re-assessments under non-orphan dossier requirements.

CONCLUSIONS: So far, turnovers of only 6 drugs exceeded the 50-million-euro threshold. Analyzed precedents show an overbalance on the side of oncology drugs. It could also be shown that especially these drugs are more able to confirm their additional benefit because studies often comply with real care situations in terms of applied therapies and evaluated endpoints. However, it is necessary to await further re-assessments of rare and high-priced drugs outside oncology to be able to draw further conclusions.

Conference/Value in Health Info

2018-11, ISPOR Europe 2018, Barcelona, Spain

Value in Health, Vol. 21, S3 (October 2018)

Code

PHP287

Topic

Health Technology Assessment

Topic Subcategory

Decision & Deliberative Processes

Disease

Multiple Diseases

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×